Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-09

AUTHORS

M. Venturini, L. Del Mastro, Franco Testore, Marco Danova, Ornella Garrone, Claudio Lanfranco, Fabio Latini, Mario R. Sertoli, Rita Lionetto, Paola Queirolo, Andrea Ardizzoni, Riccardo Rosso

ABSTRACT

To verify whether the association of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) would allow both the acceleration and the dose escalation of the cyclophosphamide/epidoxorubicin/5-fluorouracil (CEF) regimen as first-line therapy in advanced breast cancer patients, we conducted a dose-finding study. Cohorts of three consecutive patients received cyclophosphamide (Ctx, dose range 800-1400 mg/m2), epidoxorubicin (Epidx, dose range 70-100 mg/m2), and 5-fluorouracil (5-Fu, 600 mg/m2, fixed dose) given as an intravenous bolus on day 1 every 14 days; GM-CSF at 5 micrograms/kg given as a subcutaneous injection from day 4 to day 11; and EPO at 150 IU/kg given as a subcutaneous injection three times a week. In no single patient was any dose escalation allowed. A total of 14 patients entered the study. At the 4th dose level (Ctx 1400 mg/m2, Epidx 100 mg/m2, 5-Fu 600 mg/m2), two patients had dose-limiting mucositis and one patient developed dose-limiting neutropenia. Therefore, the 3rd cohort received the maximum tolerated dose, i.e. Ctx at 1200 mg/m2, Epidx at 90 mg/m2, and 5-Fu at 600 mg/m2, given every 18.5 (+/-2.5) days. Toxicity was moderate and manageable in an outpatient setting. Only 1 admission at the 4th dose level was required. Throughout the 4 dose levels there was no toxicity-related death; grade IV leukopenia ranged from 24% to 75% of cycles and grade IV thrombocytopenia ranged from 6% to 8%. No grade IV anemia was recorded. Increasing the doses of Ctx and Epidx while maintaining a fixed dose of 5-Fu with the support of both EPO and GM-CSF allows safe acceleration and dose escalation of CEF chemotherapy. Further controlled studies will evaluate the activity and efficacy of this strategy. More... »

PAGES

487-494

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002800050516

DOI

http://dx.doi.org/10.1007/s002800050516

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037076880

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/8823488


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epirubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Erythropoietin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Granulocyte-Macrophage Colony-Stimulating Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outpatients", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ospedale San Martino", 
          "id": "https://www.grid.ac/institutes/grid.410345.7", 
          "name": [
            "Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV 10, I-16132 Genova, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Venturini", 
        "givenName": "M.", 
        "id": "sg:person.01320716104.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320716104.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Martino", 
          "id": "https://www.grid.ac/institutes/grid.410345.7", 
          "name": [
            "Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV 10, I-16132 Genova, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mastro", 
        "givenName": "L. Del", 
        "id": "sg:person.0607227007.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607227007.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo", 
          "id": "https://www.grid.ac/institutes/grid.460002.0", 
          "name": [
            "Unita Operativa Oncologia, Ospedale Civile, Via Botallo 4, I-14100 Asti, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Testore", 
        "givenName": "Franco", 
        "id": "sg:person.01050555744.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050555744.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medicina Interna e Oncologia Medica, Universit\u00e0 e IRCCS San Matteo, Piazzale Golgi, I-27100 Pavia, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Danova", 
        "givenName": "Marco", 
        "id": "sg:person.0601356435.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601356435.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Martino", 
          "id": "https://www.grid.ac/institutes/grid.410345.7", 
          "name": [
            "Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV 10, I-16132 Genova, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garrone", 
        "givenName": "Ornella", 
        "id": "sg:person.0711540404.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711540404.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo", 
          "id": "https://www.grid.ac/institutes/grid.460002.0", 
          "name": [
            "Unita Operativa Oncologia, Ospedale Civile, Via Botallo 4, I-14100 Asti, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lanfranco", 
        "givenName": "Claudio", 
        "id": "sg:person.01021134576.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021134576.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Shering-Plough Italia, Direzione Medica, Via Ripamonti 89, I-20141 Milano, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Latini", 
        "givenName": "Fabio", 
        "id": "sg:person.01025266425.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025266425.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Istituto di Oncologia, Universit\u00e0, Viale Benedetto XV 10, I-16132 Genova, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sertoli", 
        "givenName": "Mario R.", 
        "id": "sg:person.01100026616.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100026616.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Epidemiologia Clinica e Sperimentazioni Cliniche Controllate, Istituto Nazionale per la Ricerca Sul Cancro, Viale Benedetto, XX"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lionetto", 
        "givenName": "Rita", 
        "id": "sg:person.01033554132.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033554132.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Martino", 
          "id": "https://www.grid.ac/institutes/grid.410345.7", 
          "name": [
            "Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV 10, I-16132 Genova, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Queirolo", 
        "givenName": "Paola", 
        "id": "sg:person.01102114523.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102114523.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Martino", 
          "id": "https://www.grid.ac/institutes/grid.410345.7", 
          "name": [
            "Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV 10, I-16132 Genova, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ardizzoni", 
        "givenName": "Andrea", 
        "id": "sg:person.0736427676.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736427676.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Martino", 
          "id": "https://www.grid.ac/institutes/grid.410345.7", 
          "name": [
            "Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV 10, I-16132 Genova, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rosso", 
        "givenName": "Riccardo", 
        "id": "sg:person.0627523114.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627523114.88"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1994.71", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003992752", 
          "https://doi.org/10.1038/bjc.1994.71"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1994.71", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003992752", 
          "https://doi.org/10.1038/bjc.1994.71"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-199112001-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005093378"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-199112001-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005093378"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(05)80347-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010534626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199405053301801", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025238022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(05)80284-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027413690"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1749-6632.1993.tb17231.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036172888"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9343(92)90678-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038113745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1989.234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046548152", 
          "https://doi.org/10.1038/bjc.1989.234"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1989.234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046548152", 
          "https://doi.org/10.1038/bjc.1989.234"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049278910"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/83.21.1546", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059816860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/85.10.801", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059817926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1988.6.9.1377", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078873341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1984.2.11.1281", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1081715796"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1994.12.12.2667", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082597536"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a058514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082770983"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1996-09", 
    "datePublishedReg": "1996-09-01", 
    "description": "To verify whether the association of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) would allow both the acceleration and the dose escalation of the cyclophosphamide/epidoxorubicin/5-fluorouracil (CEF) regimen as first-line therapy in advanced breast cancer patients, we conducted a dose-finding study. Cohorts of three consecutive patients received cyclophosphamide (Ctx, dose range 800-1400 mg/m2), epidoxorubicin (Epidx, dose range 70-100 mg/m2), and 5-fluorouracil (5-Fu, 600 mg/m2, fixed dose) given as an intravenous bolus on day 1 every 14 days; GM-CSF at 5 micrograms/kg given as a subcutaneous injection from day 4 to day 11; and EPO at 150 IU/kg given as a subcutaneous injection three times a week. In no single patient was any dose escalation allowed. A total of 14 patients entered the study. At the 4th dose level (Ctx 1400 mg/m2, Epidx 100 mg/m2, 5-Fu 600 mg/m2), two patients had dose-limiting mucositis and one patient developed dose-limiting neutropenia. Therefore, the 3rd cohort received the maximum tolerated dose, i.e. Ctx at 1200 mg/m2, Epidx at 90 mg/m2, and 5-Fu at 600 mg/m2, given every 18.5 (+/-2.5) days. Toxicity was moderate and manageable in an outpatient setting. Only 1 admission at the 4th dose level was required. Throughout the 4 dose levels there was no toxicity-related death; grade IV leukopenia ranged from 24% to 75% of cycles and grade IV thrombocytopenia ranged from 6% to 8%. No grade IV anemia was recorded. Increasing the doses of Ctx and Epidx while maintaining a fixed dose of 5-Fu with the support of both EPO and GM-CSF allows safe acceleration and dose escalation of CEF chemotherapy. Further controlled studies will evaluate the activity and efficacy of this strategy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s002800050516", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "name": "Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer", 
    "pagination": "487-494", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b09f0a0ea55781ccae4c8ab4fd5d96e62aa806f69dd3ffc666807bf4c11058a6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "8823488"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002800050516"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037076880"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002800050516", 
      "https://app.dimensions.ai/details/publication/pub.1037076880"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T17:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8672_00000490.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s002800050516"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002800050516'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002800050516'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002800050516'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002800050516'


 

This table displays all metadata directly associated to this object as RDF triples.

280 TRIPLES      21 PREDICATES      63 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002800050516 schema:about N038e5ab1b67c4e8896d88a0153d40d4e
2 N0dac867ada2e42efacbfee605f1bce05
3 N115420b28c4441a095edc88ae3d6a525
4 N158d736301ca4e38bc3e5a0ca0942b49
5 N26633d8ceb514721997ffbb15c45335f
6 N2a9fbbdf66454669887319ecd30e74fc
7 N2ff988abb28b4c64b95e4d100e79e03d
8 N45e082032b944168a67a69d100a36bbd
9 N514317d64ab9441b85ac7ba3a4db0e46
10 N82ba7540b62d442dafdb9576c3ee61a4
11 N8e02d384ecaf44d3a69b989426a1f239
12 N95fe05727c914b8198a215207872533b
13 N9b3976e25cf143d39d95610ec7f93227
14 Nb02d1d3f8db541098f6cc710a1f981e7
15 Nb037079ee5dc4ebb91276a1250ecb07f
16 Nc0605c4d418a4c2db530d66645cc1a07
17 Nc5724d0651c1486dac78fd29623cfa29
18 Ne2c44d52b9f7429bb883b157671166b1
19 Nf79e444a8c4343639164b2768c2a4d28
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author Nb8cb358cc68546e4b73d8071d56a3a05
23 schema:citation sg:pub.10.1038/bjc.1989.234
24 sg:pub.10.1038/bjc.1994.71
25 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6
26 https://doi.org/10.1016/0002-9343(92)90678-5
27 https://doi.org/10.1016/s0959-8049(05)80284-9
28 https://doi.org/10.1016/s0959-8049(05)80347-8
29 https://doi.org/10.1056/nejm199405053301801
30 https://doi.org/10.1093/jnci/83.21.1546
31 https://doi.org/10.1093/jnci/85.10.801
32 https://doi.org/10.1093/oxfordjournals.annonc.a058514
33 https://doi.org/10.1097/00000421-199112001-00002
34 https://doi.org/10.1111/j.1749-6632.1993.tb17231.x
35 https://doi.org/10.1200/jco.1984.2.11.1281
36 https://doi.org/10.1200/jco.1988.6.9.1377
37 https://doi.org/10.1200/jco.1994.12.12.2667
38 schema:datePublished 1996-09
39 schema:datePublishedReg 1996-09-01
40 schema:description To verify whether the association of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) would allow both the acceleration and the dose escalation of the cyclophosphamide/epidoxorubicin/5-fluorouracil (CEF) regimen as first-line therapy in advanced breast cancer patients, we conducted a dose-finding study. Cohorts of three consecutive patients received cyclophosphamide (Ctx, dose range 800-1400 mg/m2), epidoxorubicin (Epidx, dose range 70-100 mg/m2), and 5-fluorouracil (5-Fu, 600 mg/m2, fixed dose) given as an intravenous bolus on day 1 every 14 days; GM-CSF at 5 micrograms/kg given as a subcutaneous injection from day 4 to day 11; and EPO at 150 IU/kg given as a subcutaneous injection three times a week. In no single patient was any dose escalation allowed. A total of 14 patients entered the study. At the 4th dose level (Ctx 1400 mg/m2, Epidx 100 mg/m2, 5-Fu 600 mg/m2), two patients had dose-limiting mucositis and one patient developed dose-limiting neutropenia. Therefore, the 3rd cohort received the maximum tolerated dose, i.e. Ctx at 1200 mg/m2, Epidx at 90 mg/m2, and 5-Fu at 600 mg/m2, given every 18.5 (+/-2.5) days. Toxicity was moderate and manageable in an outpatient setting. Only 1 admission at the 4th dose level was required. Throughout the 4 dose levels there was no toxicity-related death; grade IV leukopenia ranged from 24% to 75% of cycles and grade IV thrombocytopenia ranged from 6% to 8%. No grade IV anemia was recorded. Increasing the doses of Ctx and Epidx while maintaining a fixed dose of 5-Fu with the support of both EPO and GM-CSF allows safe acceleration and dose escalation of CEF chemotherapy. Further controlled studies will evaluate the activity and efficacy of this strategy.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf N5d39494aa4d2460ca4bae9ec14a39195
45 Nd4ac27dfaa1242e58a7b6e45f7de400c
46 sg:journal.1088364
47 schema:name Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer
48 schema:pagination 487-494
49 schema:productId N133554933a7b41268030407dcc1b9f3c
50 N1910a7d88af8442ea2307b29d5fb00b6
51 N31f87a5f71a244b5aa7263d71827a5dd
52 N495a94da39e24ce6ab4eeb5931c5cf0a
53 Nccf6d4b598464bd4ad8749ea8f66bb6b
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037076880
55 https://doi.org/10.1007/s002800050516
56 schema:sdDatePublished 2019-04-10T17:26
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher N33c7428e355c45d4b815b352f6e178df
59 schema:url http://link.springer.com/10.1007/s002800050516
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N038e5ab1b67c4e8896d88a0153d40d4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Doxorubicin
65 rdf:type schema:DefinedTerm
66 N0dac867ada2e42efacbfee605f1bce05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Female
68 rdf:type schema:DefinedTerm
69 N115420b28c4441a095edc88ae3d6a525 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Breast Neoplasms
71 rdf:type schema:DefinedTerm
72 N133554933a7b41268030407dcc1b9f3c schema:name pubmed_id
73 schema:value 8823488
74 rdf:type schema:PropertyValue
75 N158d736301ca4e38bc3e5a0ca0942b49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Aged
77 rdf:type schema:DefinedTerm
78 N1910a7d88af8442ea2307b29d5fb00b6 schema:name readcube_id
79 schema:value b09f0a0ea55781ccae4c8ab4fd5d96e62aa806f69dd3ffc666807bf4c11058a6
80 rdf:type schema:PropertyValue
81 N24467282988846b7b35e90e45ba6e559 schema:name Medicina Interna e Oncologia Medica, Università e IRCCS San Matteo, Piazzale Golgi, I-27100 Pavia, Italy, IT
82 rdf:type schema:Organization
83 N26633d8ceb514721997ffbb15c45335f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Adult
85 rdf:type schema:DefinedTerm
86 N2a9fbbdf66454669887319ecd30e74fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Fluorouracil
88 rdf:type schema:DefinedTerm
89 N2ff988abb28b4c64b95e4d100e79e03d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Bone Marrow
91 rdf:type schema:DefinedTerm
92 N31f87a5f71a244b5aa7263d71827a5dd schema:name doi
93 schema:value 10.1007/s002800050516
94 rdf:type schema:PropertyValue
95 N33c7428e355c45d4b815b352f6e178df schema:name Springer Nature - SN SciGraph project
96 rdf:type schema:Organization
97 N35a96bbe497848c6975ffc02ba1a94ba rdf:first sg:person.01050555744.68
98 rdf:rest Nf4462e013ae3445c99f1c691e6d5ca8d
99 N3e07a579b11c4176b8d72493a6b7ba6d rdf:first sg:person.01021134576.97
100 rdf:rest N7baadec4f08f4dcdba4e1eb7baa230fb
101 N45e082032b944168a67a69d100a36bbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Humans
103 rdf:type schema:DefinedTerm
104 N495a94da39e24ce6ab4eeb5931c5cf0a schema:name nlm_unique_id
105 schema:value 7806519
106 rdf:type schema:PropertyValue
107 N514317d64ab9441b85ac7ba3a4db0e46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Erythropoietin
109 rdf:type schema:DefinedTerm
110 N5d39494aa4d2460ca4bae9ec14a39195 schema:issueNumber 6
111 rdf:type schema:PublicationIssue
112 N6623014127564789a6c137460021f64c schema:name Istituto di Oncologia, Università, Viale Benedetto XV 10, I-16132 Genova, Italy, IT
113 rdf:type schema:Organization
114 N7baadec4f08f4dcdba4e1eb7baa230fb rdf:first sg:person.01025266425.61
115 rdf:rest N964ad30401c447628bde8a7bc78d7a12
116 N7e663e382bec4c6e87fae308f34fbbc9 schema:name Shering-Plough Italia, Direzione Medica, Via Ripamonti 89, I-20141 Milano, Italy, IT
117 rdf:type schema:Organization
118 N82ba7540b62d442dafdb9576c3ee61a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Granulocyte-Macrophage Colony-Stimulating Factor
120 rdf:type schema:DefinedTerm
121 N8765228c668e4f15b6621e43a025b3ae rdf:first sg:person.01102114523.12
122 rdf:rest Nfc300f7894d44921bea4c43a76f37802
123 N8e02d384ecaf44d3a69b989426a1f239 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Outpatients
125 rdf:type schema:DefinedTerm
126 N95fe05727c914b8198a215207872533b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Treatment Outcome
128 rdf:type schema:DefinedTerm
129 N964ad30401c447628bde8a7bc78d7a12 rdf:first sg:person.01100026616.95
130 rdf:rest Ndeeebbb3dbdd4982a01bfcc1a2897c43
131 N98bc0dd474864ed3a1af751b855d1d0c rdf:first sg:person.0627523114.88
132 rdf:rest rdf:nil
133 N9b3976e25cf143d39d95610ec7f93227 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Middle Aged
135 rdf:type schema:DefinedTerm
136 Naad32ee1b52a4cf3bd36991037e6aa77 schema:name Epidemiologia Clinica e Sperimentazioni Cliniche Controllate, Istituto Nazionale per la Ricerca Sul Cancro, Viale Benedetto, XX
137 rdf:type schema:Organization
138 Nb02d1d3f8db541098f6cc710a1f981e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Antineoplastic Combined Chemotherapy Protocols
140 rdf:type schema:DefinedTerm
141 Nb037079ee5dc4ebb91276a1250ecb07f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Epirubicin
143 rdf:type schema:DefinedTerm
144 Nb8cb358cc68546e4b73d8071d56a3a05 rdf:first sg:person.01320716104.87
145 rdf:rest Nc20d6ca7d38f41139320e8b5fc2f91d5
146 Nc0605c4d418a4c2db530d66645cc1a07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Cyclophosphamide
148 rdf:type schema:DefinedTerm
149 Nc20d6ca7d38f41139320e8b5fc2f91d5 rdf:first sg:person.0607227007.08
150 rdf:rest N35a96bbe497848c6975ffc02ba1a94ba
151 Nc5724d0651c1486dac78fd29623cfa29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Dose-Response Relationship, Drug
153 rdf:type schema:DefinedTerm
154 Nccf6d4b598464bd4ad8749ea8f66bb6b schema:name dimensions_id
155 schema:value pub.1037076880
156 rdf:type schema:PropertyValue
157 Nd4ac27dfaa1242e58a7b6e45f7de400c schema:volumeNumber 38
158 rdf:type schema:PublicationVolume
159 Ndeeebbb3dbdd4982a01bfcc1a2897c43 rdf:first sg:person.01033554132.23
160 rdf:rest N8765228c668e4f15b6621e43a025b3ae
161 Ne2c44d52b9f7429bb883b157671166b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Pilot Projects
163 rdf:type schema:DefinedTerm
164 Ne547718964464b49974d07b1db1c8927 rdf:first sg:person.0711540404.08
165 rdf:rest N3e07a579b11c4176b8d72493a6b7ba6d
166 Nf4462e013ae3445c99f1c691e6d5ca8d rdf:first sg:person.0601356435.31
167 rdf:rest Ne547718964464b49974d07b1db1c8927
168 Nf79e444a8c4343639164b2768c2a4d28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Cohort Studies
170 rdf:type schema:DefinedTerm
171 Nfc300f7894d44921bea4c43a76f37802 rdf:first sg:person.0736427676.59
172 rdf:rest N98bc0dd474864ed3a1af751b855d1d0c
173 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
174 schema:name Medical and Health Sciences
175 rdf:type schema:DefinedTerm
176 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
177 schema:name Oncology and Carcinogenesis
178 rdf:type schema:DefinedTerm
179 sg:journal.1088364 schema:issn 0344-5704
180 1432-0843
181 schema:name Cancer Chemotherapy and Pharmacology
182 rdf:type schema:Periodical
183 sg:person.01021134576.97 schema:affiliation https://www.grid.ac/institutes/grid.460002.0
184 schema:familyName Lanfranco
185 schema:givenName Claudio
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021134576.97
187 rdf:type schema:Person
188 sg:person.01025266425.61 schema:affiliation N7e663e382bec4c6e87fae308f34fbbc9
189 schema:familyName Latini
190 schema:givenName Fabio
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025266425.61
192 rdf:type schema:Person
193 sg:person.01033554132.23 schema:affiliation Naad32ee1b52a4cf3bd36991037e6aa77
194 schema:familyName Lionetto
195 schema:givenName Rita
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033554132.23
197 rdf:type schema:Person
198 sg:person.01050555744.68 schema:affiliation https://www.grid.ac/institutes/grid.460002.0
199 schema:familyName Testore
200 schema:givenName Franco
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050555744.68
202 rdf:type schema:Person
203 sg:person.01100026616.95 schema:affiliation N6623014127564789a6c137460021f64c
204 schema:familyName Sertoli
205 schema:givenName Mario R.
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100026616.95
207 rdf:type schema:Person
208 sg:person.01102114523.12 schema:affiliation https://www.grid.ac/institutes/grid.410345.7
209 schema:familyName Queirolo
210 schema:givenName Paola
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102114523.12
212 rdf:type schema:Person
213 sg:person.01320716104.87 schema:affiliation https://www.grid.ac/institutes/grid.410345.7
214 schema:familyName Venturini
215 schema:givenName M.
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320716104.87
217 rdf:type schema:Person
218 sg:person.0601356435.31 schema:affiliation N24467282988846b7b35e90e45ba6e559
219 schema:familyName Danova
220 schema:givenName Marco
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601356435.31
222 rdf:type schema:Person
223 sg:person.0607227007.08 schema:affiliation https://www.grid.ac/institutes/grid.410345.7
224 schema:familyName Mastro
225 schema:givenName L. Del
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607227007.08
227 rdf:type schema:Person
228 sg:person.0627523114.88 schema:affiliation https://www.grid.ac/institutes/grid.410345.7
229 schema:familyName Rosso
230 schema:givenName Riccardo
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627523114.88
232 rdf:type schema:Person
233 sg:person.0711540404.08 schema:affiliation https://www.grid.ac/institutes/grid.410345.7
234 schema:familyName Garrone
235 schema:givenName Ornella
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711540404.08
237 rdf:type schema:Person
238 sg:person.0736427676.59 schema:affiliation https://www.grid.ac/institutes/grid.410345.7
239 schema:familyName Ardizzoni
240 schema:givenName Andrea
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736427676.59
242 rdf:type schema:Person
243 sg:pub.10.1038/bjc.1989.234 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046548152
244 https://doi.org/10.1038/bjc.1989.234
245 rdf:type schema:CreativeWork
246 sg:pub.10.1038/bjc.1994.71 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003992752
247 https://doi.org/10.1038/bjc.1994.71
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049278910
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1016/0002-9343(92)90678-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038113745
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1016/s0959-8049(05)80284-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027413690
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1016/s0959-8049(05)80347-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010534626
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1056/nejm199405053301801 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025238022
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1093/jnci/83.21.1546 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059816860
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1093/jnci/85.10.801 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059817926
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1093/oxfordjournals.annonc.a058514 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082770983
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1097/00000421-199112001-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005093378
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1111/j.1749-6632.1993.tb17231.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1036172888
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1200/jco.1984.2.11.1281 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081715796
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1200/jco.1988.6.9.1377 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078873341
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1200/jco.1994.12.12.2667 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082597536
274 rdf:type schema:CreativeWork
275 https://www.grid.ac/institutes/grid.410345.7 schema:alternateName Ospedale San Martino
276 schema:name Oncologia Medica 1, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV 10, I-16132 Genova, Italy, IT
277 rdf:type schema:Organization
278 https://www.grid.ac/institutes/grid.460002.0 schema:alternateName Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
279 schema:name Unita Operativa Oncologia, Ospedale Civile, Via Botallo 4, I-14100 Asti, Italy, IT
280 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...